Lineage Cell Therapeutics Partners with William Demant Invest to Develop ReSonance for Hearing Loss

Lineage Cell Therapeutics has entered a research collaboration with William Demant Invest to develop ReSonance, a treatment for hearing loss. The collaboration will cover preclinical development activities, including cell manufacturing and regulatory strategy. WDI will fund up to $12 million in research collaboration costs over the multi-year period. This collaboration aims to advance Lineage's auditory neuronal cell transplant, ANP1, and potentially support an IND/CTA filing.

Lineage Cell Therapeutics, Inc. (LCTX) has entered into a research collaboration with William Demant Invest A/S (WDI) to advance the development of ReSonance, an auditory neuronal cell transplant for the treatment of hearing loss. The multi-year collaboration, which includes an investment from WDI, will focus on preclinical development activities such as cell manufacturing, proof-of-concept studies, translational/functional models, delivery development, outcome measures, regulatory strategy, and market analysis. The goal is to support a potential IND/CTA filing for the therapy.

WDI will fund up to $12 million in research collaboration costs over the period, with development activities jointly conducted and managed by Lineage and scientists from Eriksholm Research Centre, part of Oticon A/S, a subsidiary of the Demant Group. The collaboration highlights Lineage's technology platform and the efficiency of its approach in advancing the ANP1 product concept through successful cell manufacturing and initial preclinical testing.

The partnership aims to integrate the hearing loss research expertise of Eriksholm Research Centre with Lineage's manufacturing and cell transplant expertise to explore the potential of a differentiated cell transplant and position the therapy for initial clinical development. According to the World Health Organization (WHO), nearly 2.5 billion people are expected to experience some degree of hearing loss by 2025, making this collaboration a significant step in addressing an unmet medical need.

References:
[1] https://www.marketscreener.com/news/lineage-cell-therapeutics-inc-announces-research-collaboration-with-william-demant-invest-to-devel-ce7c50ded98bf621
[2] https://www.businesswire.com/news/home/20250826289327/en/Lineage-Announces-Research-Collaboration-With-William-Demant-Invest-to-Develop-ReSonance-ANP1-for-Hearing-Loss